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Introduction: Comparative data on synovial cell infiltrate and cytokine levels in anti citrullinated peptide/protein
antibody (ACPA)-positive and ACPA negative rheumatoid arthritis (RA) patients are scarce. Our aim was to analyze
synovial cell infiltrate and synovial fluid (SF) levels of cytokines in patients with RA according to the presence or
absence of ACPA in serum.
Methods: A cross-sectional study in a single center including consecutive RA patients was performed. Patients were
defined as 'ACPA negative' if serum was negative to two different ACPAs [second generation commercial anti-cyclic
citrullinated peptide antibodies (CCP2) and chimeric fibrin/filaggrin citrullinated antibodies]. Parallel synovial tissue
(ST) biopsies and SF were obtained by knee arthroscopy. Synovial cell infiltrate and endothelial cells were analyzed
by immunohistochemistry and SF levels of Th1, Th2, Th17 and pro-inflammatory cytokines by Quantibody(R)
Human Array.
Results: A total of 83 patients underwent arthroscopy, with a mean age of 55.9 ± 12 years, and mean disease duration
of 45 months (interquartile range, IQR 10.8 to 122). 62% were female and 77% were ACPA positive. No significant
differences were found in clinical variables, acute phase reactants, synovial cell infiltrate or lymphoid neogenesis (LN)
between ACPA positive and negative patients. However ACPA positive patients had significantly higher levels of
IL-1β, IL-10, IL-17 F and CC chemokine ligand 20 (CCL-20) than ACPA negative patients.
Conclusions: In our cohort of patients with RA no significant differences were found in synovial cell infiltrate or synovial
LN according to ACPA status. However, ACPA positive patients had higher levels of T-cell derived and pro-inflammatory
cytokines than ACPA negative patients. As systemic and local inflammation was similar in the two groups, these findings
support a distinct synovial physiopathology.Introduction
Rheumatoid arthritis (RA) is a heterogeneous chronic in-
flammatory disease conditioned by genetic, environmental
and immunological factors, mainly autoantibodies. There
is evidence that RA patients positive for rheumatoid
factor (RF) and anti-citrullinated peptide/protein anti-
bodies (ACPA) have more severe disease and poorer
outcomes [1]. ACPA-positive RA patients develop earlier* Correspondence: sanmarti@clinic.cat
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distribution, and reproduction in any mediumand more widespread erosions than consistently ACPA-
negative patients [1]. It has been suggested that although
early clinical phases could be similar in ACPA positive and
negative patients, ACPA positive RA patients develop more
structural damage [2] and more cardiovascular disease dur-
ing follow-up [3].
Different peptides/proteins present in the synovial
membrane have been proposed as in vivo antigens for
anti-citrullinated antibodies, including mutated vimentin
[4], fibrinogen [5] and α-enolase [6]. Different citrulli-
nated antigenic substrates have been developed in orderCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for RA diagnosis, showing a good but not absolute cor-
relation between them [7]. Our group demonstrated that
a homemade ACPA ELISA test, using chimeric fibrin/
filaggrin citrullinated synthetic peptides (CFFCP) [8] had
a high sensitivity and specificity for RA, and was able to
detect some patients negative to commercial anti-cyclic
citrullinated peptide antibodies (CCP2), the most com-
mon test used in clinical practice. Additionally, early RA
patients who were positive for anti-CFFCP had a poor
radiological outcome [9].
Despite the body of knowledge of the different clin-
ical phenotype of RA patients according to ACPA sta-
tus, there is limited data on their synovial fluid (SF)
cytokine levels and the characteristics of synovial mem-
brane infiltrates [10-12]. Given that differences in syn-
ovial cell infiltrate between RA and spondyloarthropathy
(SpA) have been described, with significantly more mast
cells [13], neutrophils (innate immunity) and endothelial
cells in SpA [14], the objective of this study was to
analyze whether these cells are also overrepresented
in ACPA negative RA patients, and whether cells re-
lated to adaptive immunity (T and B cells and lymphoid
neogenesis structures) are more abundant in ACPA
positive patients. We also analyzed T-cell derived and pro-
inflammatory cytokine levels in SF of RA patients accord-
ing to ACPA status.
Methods
We conducted a cross-sectional study in a single center
that included patients undergoing rheumatologic arthros-
copy from a cohort of 300 consecutive RA patients at-
tending the Rheumatology Department, Hospital Clinic,
Barcelona, Spain, a tertiary referral center. Patients with
long-standing disease (>20 years of evolution) were ex-
cluded. All patients gave informed consent, and the study
was approved by the Ethics Committee of the Hospital
Clinic of Barcelona, Barcelona, Spain.
Selection of sample
All patients fulfilled American College of Rheumatology
(ACR) 1987 classification criteria [15] according to clin-
ical judgment at diagnosis. Data were recorded using a
specifically-created standard data collection form and
included detailed demographic, clinical and laboratory
variables. RF was determined by nephelometry, CCP2
antibodies by ELISA (Eurodiagnostica) and anti-CFFCP
by a home-made ELISA, as previously described [9].
RA patients negative for both ACPA antibody tests
were classified as seronegative and patients positive at
least for one of the antibodies (CCP2 or CFFCP) before
arthroscopy as seropositive.
Patients who fulfilled criteria for another inflammatory
arthropathy during follow-up, mainly psoriatic arthritis(PsA) (CASPAR critera) [16], SpA (European Spondy-
loarthropathy Study Group) [17] or systemic lupus ery-
thematosus (ACR criteria 1997) were excluded [18].
Synovial samples were obtained by knee arthroscopy.
The indication for diagnostic (exclusion of other causes
of knee arthritis) or therapeutic (lavage with four liters
of saline and glucocorticoid infiltration) arthoscopy was
made by clinical judgment in patients with an actively
inflamed knee, defined as a swollen joint with inflam-
matory SF. Arthroscopy was performed with a 2.7 mm
arthroscope (Storz, Tuttlingen, Germany) under local
anesthesia.
Immunohistochemistry of synovial tissue
Synovial biopsies were fixed in 10% neutral formalin and
embedded in paraffin, sectioned, and subjected to antigen
retrieval by microwave heating in 1 mM ethylenediamine-
tetraacetic acid (EDTA) for 15 minutes when required. The
slides were subsequently stained with an automated immu-
nostainer (TechMate 500 Plus; Dako, Cambridge, UK)
using the following monoclonal antibodies: anti-CD3
(clone PS1; Novocastra, Newcastle, UK), anti-CD20 (clone
L26; Dako), anti-CD15 (clone BY87; Novocastra), anti-
CD31 (clone JC70A; Dako), anti-CD68 (clone KP-1; Dako),
anti-CD117 (mast cells, rabbit anti-human polyclonal anti-
body; Dako).
As a negative control, primary antibodies were
substituted by non-immune matched immunoglobulins.
Primary antibodies were subsequently detected by an
avidin-biotin-peroxidase-based method (Envision System;
Dako) and an aminoethylcarbazole color reaction (Sigma-
Aldrich, St. Louis, MO, USA), as described previously in
detail [19]. Finally, the slides were counterstained with
hematoxylin.
Lymphocytes (CD3, CD20), neutrophils (CD15), macro-
phages (CD68), mast-cells (CD117) and vessels (endothelial
cells, CD31) were quantified by Digital Image Analysis
(Olympus®, Tokyo, Japan) by an expert (RC) blinded to the
clinical data [19]. We also evaluated the presence of lymph-
oid neogenesis (LN) as defined by the presence of follicular
aggregates grade ≥2 (>6 radial B-cells) with T/B cell segre-
gation and high endothelial venules (that is, MECA-79 epi-
tope positive) [20]. We have previously demonstrated that
this definition correlates well with synovial tissue (ST) ex-
pression of LN-associated chemokines [21].
Cytokine analysis in synovial fluid
SF concentrations (pg/ml) of Th1, Th2, Th17 and pro-in-
flammatory cytokines were determined by Quantibody®
Human Th17 Array (RayBiotech, Norcross, GA, USA) and
included Granulocyte macrophage-colony stimulating
factor, (GM-CSF), IFNγ, -1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12p70, IL-13, IL-17, IL-17 F, IL-22, IL-23, CCL 20, trans-
forming growth factor (TGF)-β1, TNFα, and TNFβ.
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for simultaneous measurements of multiple cytokines [22].
Statistical analysis
Several variables were dichotomized for the analysis. Pa-
tients were labeled as seronegative if they were negative
for both antibodies, as described above. Patients were
compared according to ACPA status. For immunohisto-
chemistry analysis, we first stratified the cohort in two
categories (ACPA positive and APCA negative), but we
also made a sensitivity analysis dividing the cohort in
two subcategories: ACPA negative and ACPA positive at
high titers, using the CCP2 test (>1,600 IU). Differences
in means in normally distributed variables were analyzed
using the parametric T-test, and variables without a nor-
mal distribution were assessed using Wilcoxon’s test.
Correlations were assessed using either the Pearson cor-
relation test for normally distributed data or Spearman’s
P when data were not normally distributed. Multiple re-
gression models were used for disease activity and dis-
ease duration adjustments. The analysis was made using
the IBM SPSS v20 statistical package.
Results
The study included 83 patients with RA who underwent
rheumatologic arthroscopy, with a mean age at arthros-
copy of 55.9 ± 12 years, and mean disease duration of
45 months (interquartile range (IQR) 10.8 to 122 months).
Of the 83 patients, 62% were women, 88% were white, 74%
had erosive disease and 31% extra-articular disease. A total
of 26 (31%) were receiving biological treatment. RF was
positive in 65 (78%) and ACPA in 64 (77%) patients; nine
patients were positive for anti-CFFCP and negative for
anti-CCP2, while four patients were positive for CCP2 but
negative for anti-CFFCP. Forty-four patients were positive
for both antibodies.
No clinically important differences were found be-
tween ACPA positive and ACPA negative patients. Both
groups had a similar profile in terms of disease duration,
clinical disease activity, remission rates, biological activ-
ity (erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels), erosive disease, disability and
treatment (Table 1). As expected, RF was more prevalent
in ACPA positive patients (87% versus 47%, P = <0.001).
Synovial tissue infiltrate and lymphoid neogenesis are
similar between ACPA negative and positive rheumatoid
arthritis patients
When the immunohistochemical analysis of synovial
membrane was compared according to ACPA status
(positive versus negative), including CD3 (T-cell), CD20
(B-cell), CD15 (neutrophils), CD68 (macrophages) in lin-
ing and sublining, CD117 (mast cells) and vessels (CD31,
endothelial cells), there were no significant differencesbetween the two groups (Figure 1 and Table 2). LN was
more prevalent in ACPA negative patients, but without sig-
nificant differences (58.8% versus 39.5%, = 0.119). Stratifica-
tion of patients into ACPA positive at the highest titers
(CCP2 >1,600 IU) and ACPA negative showed no signifi-
cant differences in ST infiltrates. Once again, LN was non-
significantly more prevalent in ACPA negative patients
(58.8% versus 25%, = 0.71) (Additional file 1: Table S1).
We also evaluated the immunohistochemical findings
adjusted by disease activity and disease duration, but
no differences in ST infiltrate were found according to
these factors in the multivariate regression model (data
not shown).
ACPA positive rheumatoid arthritis patients have higher
levels of IL-17 F, CCL20, IL-1β and IL-10 in synovial fluid
SF analysis was available for 51 patients (40 ACPA
positive/11 negative). Except for the expected higher
RF positivity, there were no significant clinical differences
between the two groups (Table 3). ACPA positive patients
had significantly higher levels of IL-17 F, CCL20, IL-1β
and IL-10 than ACPA negative patients (Figure 2). No dif-
ferences in other cytokines, including IL-6 and tumor ne-
crosis factor alpha (TNFα), were found (Table 4).
There were weak significant correlations between SF
CCL20 and disease activity as measured by the disease
activity score in 28 joints (DAS28) at baseline (r = 0.32;
P = 0.028, respectively). SF CCL20 levels also significantly
correlated with CD-15+ cell count (neutrophils/mm2)
(r = 0.42; = 0.011) in ST. No other correlations were
found.
Discussion
We hypothesized that ACPA positive and negative pa-
tients might exhibit differences in ST cellularity with re-
spect to innate and adaptive immune cells and T-cell
derived cytokine levels. We found higher SF levels of IL-
1β, IL-10, IL-17 F and the CCL20 chemokine in ACPA
positive patients in comparison with ACPA negative pa-
tients. However, we found no significant differences in syn-
ovial cell infiltrates or in LN according to ACPA status.
These results are underlined by the fact that the two
groups were very similar in terms of biological and clinical
disease activity. Additionally, the results did not vary after
adjustment of cell infiltrate in ST and cytokines levels in SF
according to disease activity and disease duration.
Previous studies have reported that ACPA positive and
negative RA patients have different susceptibility genes
and a different disease course [23]. The HLA shared epi-
tope and PTPN22 [24] predispose to ACPA-positive RA,
whereas HLA-DRB1*03 and IRF5 [25] predispose to
ACPA-negative disease.
Few studies have focused on synovial differences in
RA patients according to ACPA status [10-12]. As in the
Table 1 Clinical characteristics of 83 patients with arthroscopy
Variables Total ACPA positive ACPA negative P value
Number = 83 Number = 64 Number = 19
Sex (Female%) 62 64 58 0.62
Age at arthroscopy (Mean, SD) 55.98 ± 12.7 55.29 ± 12.8 58.23 ± 12.3 0.47
Disease duration to arthroscopy (Median, IQR 25 to 75) months 45.50 (10.8–122.1) 34.56 (8.8–122.0) 79.0 (15.1–126.8) 0.27
Rheumatoid factor (%) 78 87 47 <0.001*
Extra-articular disease (%) 31 35 20 0.28
Erosive disease (%) 74 72 76 0.73
CRP mg/dl (Median, IQR 25 to 75) 2.32 (1.0–5.3) 2.95 (1.0–5.9) 1.43 (0.7–3.7) 0.21
ESR mm (Median, IQR 25 to 75) 32 (16.0– 64.0) 37 (17.5–70.0) 26 (14.7–39) 0.07
DAS28 (Median, IQR 25 to 75) 4.74 (3.6–5.5) 4.81 (3.7–5.5) 4.74 (3.2–5.5) 0.52
mHAQ (Median, IQR 25 to 75) 1.19 (0.5–1.5) 1.25 (0.6–1.6) 0.56 (0.2–0.7) 0.10
Number of DMARDs (ever), Mean (SD) 2.20 (1.1) 2.20 (1.1) 1.86 (1.1) 0.89
Methotrexate (%), ever 88.4 88.9 88.7 0.98
Biologic treatment (%, before arthroscopy) ever 40.6 40.0 42.0 0.85
ACPA, anti citrullinated peptide/protein antibodies; CRP, C-reactive protein; DAS-28, disease activity score −28 joints; DMARDs, disease-modifying anti-rheumatic
drugs; ESR, erythrocyte sedimentation rate; IQR, interquartile range; mHAQ, Modified Health Assessment Questionnaire, SD, standard deviation; SJC, swelling joint
count; TJC, tender joint count. *p value is significant if <0.05.
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differences in cell infiltrates in ST from 54 RA patients
analyzed (37 ACPA positive and 17 ACPA negative).
In contrast, van Oosterhout et al. [11] found a higher
number of infiltrating lymphocytes and higher expres-
sion of CD3, CD8, CXCL12 and CD45RO in 34 ACPA
positive patients in comparison with 23 ACPA negative
patients, suggesting that ACPA is associated with a
higher number of cells from the acquired immune
system. The differences persisted after correction for
DAS28. Conversely, ACPA negative patients had more ex-
tensive signs of fibrosis [11], a rather non-specific findingFigure 1 Microscopic analysis of synovial inflammation with immuno
(CD68+) in ACPA positive (+) versus ACPA negative (−) RA. Original m
RA, rheumatoid arthritis.generally associated with longer disease duration and re-
sidual synovitis.
Mast cells have recently been shown to be the main
producers of IL-17 in ST in RA [26] and SpA [13], al-
though they are significantly more abundant and produce
more IL-17 in ST of SpA than in RA [13]. Neutrophils
also produce IL-17 and are over-represented in ST of
SpA compared with RA [27]. Our results show that mast
cells, neutrophils and macrophages, cells from the innate
immune system, are similarly represented in ST of ACPA
positive and negative RA patients. This finding is in line
with a recent report by Suurmond et al. [12] that foundstaining for T-cells (CD3+), B-cells (CD20+) and macrophages
agnification × 20. ACPA, anti-citrullinated peptide/protein antibodies;
Table 2 Immunohistochemistry characteristics according to ACPA status
Synovial cells Total number = 83 ACPA positive number = 64 ACPA negative number = 19 P value
CD3/mm2 (Median, IQR 25 to 75) 509.90(210.7–821.6) n = 70 514.10 (198.9–821.6) N = 54 509.30 (233.8–898.2) n = 16 0.823
CD20/mm2 (Median, IQR 25 to 75) 126.52 (30.3–242.6) n = 70 117.90 (26.6–235.4) n = 54 162.73 (42.2–315) n = 16 0.386
CD20 cell grade 3 follicles (Median, IQR 25 to 75) 0 (0–2.7) n = 72 0 (0–2) n = 55 2.0 (0–3.5) n = 17 0.221
CD68L/mm2 (Median, IQR 25 to 75) 293.34 (94.2–453.4) n = 63 305.59 (94.2–438.5) n = 47 204.74 (93.5–532.2) n = 16 0.813
CD68SL/mm2 (Median, IQR 25 to 75) 677.17 (3.1–1665.5) n = 63 738.50 (379.3–2016.7) n = 47 526.74 (271.5–874.9) n = 16 0.138
CD15/mm2 (Median, IQR 25 to 75) 58.46 (10–204.4) n = 49 71.90 (9.0–445.4) n = 35 35.74 (9.9–88) n = 14 0.278
CD117/mm2 (Median, IQR 25 to 75) 40.26 (20.8–55) n = 51 39.27 (21.2–54.5) n = 37 42.81 (19.1–75.6) n = 14 0.473
CD31/34 (Median, IQR 25 to 75) 46.31 (37.4–64.1) n = 44 53.66 (36.8–68.8) n = 31 43.56 (34–63) n = 13 0.425
LN (%) 40.80 39.50 58.80 0.119
ACPA, anti-citrullinated peptide/protein antibodies; IQR, interquatile range; LN, lymphoid neogenesis; n, number.
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lymphocytes and CD68 macrophages in ST of ACPA
positive and negative RA patients.
We have previously shown that seronegative RA (RF
negative) patients predominantly exhibited a synovial
vascular pattern characterized by tortuous vessels [28]
similar to that found in patients with SpA [29]. Further-
more, these patients had a higher density of synovial ves-
sels, as determined by CD31, and less radiographic damage
than seropositive (RF positive) patients. However, in the
present study we found no differences in synovial vessel
density or radiographic damage. A possible explanation is
that our present cohort of ACPA negative patients may
represent some selection bias to a more aggressive disease
than usual in this type of patients, as demonstrated by the
same level of disease activity, frequency of erosive disease
and the need for DMARDs and biological therapy as
ACPA positive patients.
Synovial LN, as previously defined, might act as an ec-
topic lymphoid organ [30]. Recently, our group analyzedTable 3 Comparison of patients with SF cytokine analysis
Variables Total number =
Sex (female,%) 64.7
Age at arthroscopy, years (Mean, SD) 56.8 ± 12.1
Disease duration to arthroscopy (months),
Median (IQR 25–75)
52.0(12.2–134.3) N
Rheumatoid factor (%) 82
Erosive disease (%) 72
Extra-articular disease (%) 37
DAS28, Median (IQR 25–75) 5.06 (3.9–5.8) N =
ESR mm/hr (before arthroscopy), Median (IQR 25–75) 43 (22–70) N = 4
CRP mg/dl (before arthroscopy), Median (IQR 25–75) 3.0 (1.2–6.2) N =
DMARDs (Mean, SD) 2.61 ± 1.50
Biologic treatment (%) ever 49
Data are expressed as median (IQR) or as percentage. CRP, C-reactive protein; DMA
rate; mHAQ, Modified Health Assessment Questionnaire; IQR, interquartile range; SF
significant if < 0.05.the clinical significance of LN in 86 patients with RA
[19]. LN was found in around 50% of patients, and was
associated with longer disease duration and greater use
of anti-TNF therapy. LN was not correlated with other
clinical characteristics such as disease activity or RF or
ACPA antibodies. After multivariate logistic regression,
LN was an independent predictor of a worse response to
therapy. In the present study we found no association
between synovial LN and ACPA status, confirming the
results of previous studies [19,31,32]. Furthermore, we
found a slightly higher prevalence of LN in ACPA nega-
tive patients, as have other studies [32]. These results
are not unexpected, because synovial LN has also been
described in around 40% of patients with PsA, a disease
with no specific autoantibodies [21]. Therefore, although
experimental models suggest that ACPA are produced
by plasma cells associated with germinal centers in RA
ST [33], clinical studies have failed until now to demon-
strate an association between synovial LN and the pres-
ence or absence of ACPA in serum or SF (28). Thus, the51 ACPA positive number = 40 ACPA negative N = 11 P value
65.0 63.6 0.93
58.5 ± 12.2 58.3 ± 1mber2.2 0.64
= 47 39.3 (8.7–134.3) N = 39 87.9(45.7–147.4) N = 8 0.32
90 54 0.006*
72 70 0.87
40 25 0.41
47 5.06 (4.0–5.7) N = 37 5.13 (3.8–5.9) N = 10 0.81
7 43 (24–71) N = 37 27 (16–66) N = 10 0.42
47 3.1 (1.1–6.6) N = 37 2.2 (1.1–6.3) N = 10 0.82
2.43 ± 1.48 3.27 ± 1.60 0.10
40 82 0.014*
RDs, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation
, synovial fluid; SJC, swelling joint count; TJC, tender joint count. * p value is
Figure 2 Differential expression of cytokines in SF ACPA positive and negative patients. (A. IL-1β, B. IL-10, C. IL-17 F, D. CCL20). SF
concentrations (pg/ml) were determined by Quantibody® Human Th17 Array (RayBiotech, Norcross GA, USA). Wilcoxon’s test was used to
compare means in A-D. ACPA, anti-citrullinated peptide/protein antibodies; SF, synovial fluid.
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to be elucidated. We recently reported data supporting
the idea that synovial LN in PsA could be associated
with a different pattern of cytokines that are related to
the IL-17/IL-23 pathway [34].
Although our results showed no significant differences
in synovial LN between ACPA positive and negative RA
patients, we found higher levels of cytokines (IL-1, IL-
10, IL-17 F) and the CCL20 chemokine in SF of ACPA
positive patients. IL-1 has a clear pro-inflammatory role
in RA through stimulation of multiple inflammatory me-
diators, including cytokines, chemokines and metallopro-
teases. IL-10 seems to have a more complex functional
role, acting as an anti-inflammatory cytokine, but may
also stimulate the humoral response and, thus, lead to
autoantibody production. In fact, IL-10 may also havepro-inflammatory actions, as shown by reports of an asso-
ciation between IL-10 levels and radiological progression
in RA [35,36].
IL-17 F is an isoform of IL-17A and has similar bio-
logical effects, with a key role in neutrophilic inflamma-
tion. Although Th17 cells originally appeared to be the
greatest producers of IL-17, recent studies have shown
the scarcity of T cells producing IL-17 in RA synovitis,
with mast cells and neutrophils being the main source of
synovial IL-17 [26].
SF levels of CCL20, a chemokine ligand for CCR6+
cells, included Th17 cells, correlated with disease activity
and were also significantly higher in ACPA positive pa-
tients. Furthermore, SF CCL20 levels correlated with
neutrophilic infiltration in ST. All these results are in line
with previous findings by Melis et al. [37], and confirm
Table 4 Comparison of cytokine profile in SF according to ACPA status (number = 51)
SF cytokines Total ACPA positive ACPA negative P value
Number = 51 Number = 40 Number = 11
GM-CSF (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.461
IFNγ (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.828
IL-1β (pg/ml) 0 (0 to 7.9) 2.61 (0 to 12.2) 0 (0 to 0) 0.011
IL-2 (pg/ml) 0 (0 to 159.3) 38.9 (0 to 164) 0 (0 to 0) 0.076
IL-4 (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.280
IL-5 (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.714
IL-6 (pg/ml) 1,252.6 (4.3 to 47.4) 1,260.8 (774.9 to 1,725.1) 1,170.6 (628.8 to 1,568.4) 0.697
IL-10 (pg/ml) 16.2 (4.3 to 47.4) 26.7 (6.9 to 57.1) 0 (0 to 13.4) 0.001
IL-12p70 (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.682
IL-13 (pg/ml) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.688
IL-17 (pg/ml) 0 (0 to 26.2) 0 (0 to 33.2) 0 (0 to 0) 0.160
IL-17 F (pg/ml) 142.7 (0 to 532.6) 269.9 (23.1 to 534.8) 9.2 (0 to 71.2) 0.021
IL-21 (pg/ml) 783 (0 to 1,162.4) 820.8 (0 to 1,158.3) 0 (0 to 1,381.4) 0.493
IL-22 (pg/ml) 0 (0 to 0) 0 (0 to 91.8) 0 (0 to 0) 0.207
IL-23 (pg/ml) 259 (0 to 863.1) 311.7 (0 to 1,028.4) 169.4 (0 to 472.3) 0.372
CCL20 (pg/ml) 445.5 (59.0 to 3,521.1) 1,437.9 (179.3 to 3,928.0) 39.2 (5.6 to 161.9) <0.0001
TGF-β1 (pg/ml) 768 (0 to 1,927.7) 924.4 (0 to 1,918.3) 0 (0 to 2,035.3) 0.277
TNFα (pg/ml) 0 (0 to 16.3) 0 (0 to 16.2) 0 (0 to 17.6) 0.636
TNFβ (pg/ml) 0 (0 to 13.1) 0 (0 to 13) 0 (0 to 15.2) 0.759
Data are expressed as median (IQR). CCL20: CC chemokine ligand 20, GM-CSF: Granulyte macrophage-colony stimulating factor, TGF: Transforming growth factor,
TNF: Tumor necrosis factor.
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had significantly higher levels of IL-17 in SF compared
with ACPA negative patients [12], suggesting that the
IL-17 pathway may play a greater role in the pathogenesis
of ACPA positive RA.
Our study has several strengths and limitations. First,
we defined ACPA status using two different techniques,
which allowed more accurate classification, that is, we
classified patients as seronegative only when they were
negative for both antibodies. We also analyzed patients
according to ACPA at high titers versus ACPA negative.
Secondly, the study sample was well balanced, without
significant differences in terms of clinical characteristics,
suggesting that our results reflect phenomena occurring
in SF and the synovial membrane that are probably not
influenced by disease duration or disease activity. Thirdly,
we made a broad synovial assessment, analyzing not only
various lines of cell infiltrates and LN in order to compare
the relevance of innate or acquired immune cells in each
patient group, but also the cytokines associated with Th1,
Th2, and Th17 cells. To our knowledge, this is the first
study to determine such a broad spectrum of SF cytokines
according to ACPA status. A few studies have analyzed
a smaller number of cytokines (IL-17, IL-15 or IL-33)
[12,38,39] according to ACPA status. Serum levels of
IL-33 were significantly higher in patients with high ACPAconcentrations [39], whereas serum IL-17 [12] and IL-15
[38] levels were slightly, but non-significantly, higher in
ACPA positive patients.
We included one of the largest cohorts of patients
with parallel ST and SF samples. However, there were a
limited number of ACPA negative patients, even though
the proportion reflected well the clinical reality in our
setting (around 25%). Likewise, as our hospital is a ref-
erence center for inflammatory arthritis, our patients
could be a selected sample of RA patients. However, we
found no significant differences in our cohort compared
with other cohorts comprising mainly white patients
[40]. In addition, there was no systematic protocol to
determine the indication for arthroscopy. The study
was conducted in daily clinical practice and the indica-
tion for arthroscopy was made according to clinical
judgment. It is interesting to note that although the dif-
ferent clinical characteristics including the level of dis-
ease activity were similar between ACPA positive and
negative patients, biologic use was more frequent in the
latter group, therefore a pharmacological effect on the
synovial cytokine profile cannot be ruled out. Finally,
given that the majority of our patients were white, our
results must be interpreted carefully and must be con-
firmed in other populations with different racial/ethnic
distributions.
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We found no significant differences in synovial cell infil-
trates nor in LN according to the ACPA status in our
cohort of patients with RA. However, ACPA positive
patients had higher levels of the IL-17 pathway-related
cytokines/chemokines. Given that there were no differ-
ences between ACPA positive and negative patients with
respect to systemic or local inflammation, these results
suggest different pathogenic mechanisms in ACPA posi-
tive and negative RA patients.
Additional file
Additional file 1: Table S1. Immunohistochemistry characteristics
quantified by Digital Image Analysis according to CCP titers (CCP2 high
titers versus ACPA negative).
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